Are corticosteroids recommended as primary treatment for Guillain‑Barré syndrome?

Corticosteroids Are Not Recommended for Guillain-Barré Syndrome

Corticosteroids should not be used as primary treatment for Guillain-Barré syndrome, as they provide no benefit and oral corticosteroids may actually worsen outcomes. 1, 2

Evidence Against Corticosteroid Use

The evidence against corticosteroids in GBS is robust and consistent across multiple high-quality guidelines:

• Eight randomized controlled trials demonstrated no significant benefit from corticosteroids in GBS, and oral corticosteroids specifically showed negative effects on patient outcomes 1

• The 2023 EAN/PNS guideline explicitly recommends against using oral corticosteroids and weakly recommends against IV corticosteroids based on GRADE methodology 2

• A 2021 network meta-analysis of 2,474 patients from 28 trials confirmed that corticosteroids have no considerable impact on GBS, with methylprednisolone and prednisolone showing no improvement compared to placebo 3

• The 2006 Cochrane review found that oral corticosteroids significantly slow recovery from GBS (weighted mean difference of 0.82 disability grade less improvement at 4 weeks) 4

Recommended Treatment Instead

The proven effective treatments for GBS are intravenous immunoglobulin (IVIg) or plasma exchange (PE), not corticosteroids:

• IVIg 0.4 g/kg daily for 5 days is recommended for patients unable to walk unaided within 2 weeks of weakness onset 1, 2

• PE (200-250 ml plasma/kg in 4-5 sessions) is equally effective to IVIg and recommended within 4 weeks of onset for non-ambulatory patients 1, 2

• IVIg is typically preferred over PE because it is easier to administer and more widely available 1

Important Caveats

Combination Therapy Does Not Help

• PE followed by IVIg is no more effective than either treatment alone 1
• Insufficient evidence exists for add-on intravenous methylprednisolone with IVIg 1

Exception: Acute-Onset CIDP

• Corticosteroids may be considered only if the diagnosis changes to acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP), which should be suspected if progression continues beyond 8 weeks from onset (occurs in ~5% of initially diagnosed GBS patients) 2, 5

Conflicting Data on Subtypes

One 2022 retrospective study from Southern China suggested high-dose glucocorticoids might benefit AIDP subtype patients specifically 6. However, this contradicts the preponderance of high-quality guideline evidence and should not change clinical practice, as the 2023 EAN/PNS guideline explicitly does not endorse treatment decisions based on electrophysiological subtype 2, 7.

Clinical Algorithm

For patients with GBS unable to walk unaided:

1. Initiate IVIg 0.4 g/kg/day × 5 days within 2 weeks of weakness onset 2
2. If IVIg unavailable or contraindicated, use PE within 4 weeks of onset 2
3. Do not add corticosteroids 1, 2
4. If progression continues >8 weeks, reconsider diagnosis as A-CIDP and then consider corticosteroids 2, 5